Pipecolic Esters Inhibit Proteasome via Alpha-Ring Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current proteasome inhibitors used in cancer treatment are toxic and develop resistance, and there is a lack of effective allosteric proteasome modulation strategies.
Innovation Solution
Development of compounds with specific structures that target the 20S proteasome's α-ring, inhibiting proteolytic activity without affecting the mTOR pathway, and are capable of modifying the proteasome in cells to treat uncontrolled cellular proliferation disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current proteasome inhibitors are used for cancer treatment, then proteasome activity is inhibited, but toxicity and resistance development occur
Solution Approach 1:
The patent introduces an intermediary compound (pipecolic acid derivative) that indirectly inhibits proteasome activity by binding to the α-ring region, rather than directly competing with substrate at the catalytic site. This intermediary mechanism of action provides effective proteasome inhibition while avoiding the toxicity and resistance issues associated with conventional direct inhibitors like boronic acids and epoxysuccinyl compounds.
Solution Approach 2:
The patent changes the binding parameter location from the catalytic β-subunit site to the α-ring region of the proteasome. By altering the binding site parameter, the compound achieves proteasome inhibition through a different mechanism, resulting in improved therapeutic profile with reduced toxicity and resistance development compared to conventional inhibitors.
2Reliability
If rapamycin and its metabolites are used, then proteasome inhibition is achieved, but mTOR pathway interference occurs
Solution Approach 1:
The patent applies local quality by designing a compound that specifically targets the α-ring region of the proteasome with high selectivity. The pipecolic acid derivative structure is optimized to bind locally at the α-ring interface, providing focused proteasome inhibition without affecting other pathways such as mTOR, thus achieving high adaptability and selectivity.
3Reliability
If competitive inhibitors targeting catalytic subunits are used, then proteasome activity is blocked, but allosteric modulation potential is lost
Solution Approach 1:
Instead of following the conventional approach of designing competitive inhibitors that bind to catalytic subunits, the patent inverts the strategy by developing an inhibitor that binds to the α-ring region. This inverted approach enables allosteric modulation of proteasome activity, providing a more complex but effective inhibition mechanism that overcomes the limitations of simple competitive inhibition.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present disclosure relates to chemical compounds that modulate proteasome activity, pharmaceutical compositions containing such compounds, and use of these compounds and compositions for the treatment of disorders of uncontrolled cellular proliferation such as, for example, a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.